Loading organizations...
Quin Capital is an investment firm specializing in the insurance and service contract industries, providing capital and strategic partnership. Leveraging deep industry expertise, it actively participates in portfolio companies' development, offering board-level governance and guidance on creative risk management. This approach goes beyond traditional funding to ensure robust expansion.
Established by a collective of successful insurance industry veterans, Quinn Capital recognized a critical need for specialized investment and operational support. This group, with extensive acumen, founded the firm to actively deploy experience and capital. Their model emphasizes hands-on involvement, fostering sustained success in complex risk environments.
Quinn Capital primarily serves companies in the insurance and service contract sectors seeking both capital and expert strategic partnership. Its vision is to be a pivotal growth catalyst for innovative ventures in these specialized markets, ensuring portfolio companies receive essential funding and vital industry knowledge to establish new benchmarks.
Quin Capital has 1 tracked investment across 1 company. The latest tracked deal is $76.0M Series A in Interius BioTherapeutics in May 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2021 | Interius BioTherapeutics | $76.0M Series A | Cormorant Asset Management, Tomas Kiselak | Agent Capital, Bain Capital Life Sciences, Cofounders Capital, American Cancer Society, BrightEdge, Knollwood Investment Advisory, Logos Capital, Longwood Fund, Osage University Partners, RA Capital Management, Lonnie Moulder JR, The Mark Foundation For Cancer Research, University OF Pennsylvania |